Examining the Link Between Heart Disease and HIV Infection in Women
NCT ID: NCT00312468
Last Updated: 2018-07-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1011 participants
OBSERVATIONAL
2006-10-31
2012-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
HIV and Cardiovascular Risk
NCT00465426
HIV-Associated Heart Disease
NCT00005229
Cardiovascular Radiologic and Metabolic Assessment in HIV: An Investigation of Pathophysiology
NCT01089114
Cardiovascular Diseases in HIV-infected Patients HIV-HEART Study: 5 Years Follow-up
NCT01196273
Impact of Antiretroviral Therapy on Cardiac Biomarkers
NCT00641888
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This 4-year study will enroll 750 HIV infected women and 250 HIV uninfected women who are participating in the WIHS study. Participants will undergo an initial ultrasound imaging of the neck to measure the size and thickness of the arteries. They will return for a repeat ultrasound at Years 2, 3, and 4 to assess any progression of atherosclerosis. Data from the participants' biannual WIHS study visits, including HIV medication usage, viral load and CD4 test results, and occurrence of AIDS and other illnesses, will be reviewed. Results of participant's inflammation marker tests, which may indicate the presence of atherosclerosis, including white blood cell count, C-reactive protein, E-selectin, and intercellular adhesion molecule 1, will also be reviewed.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
21 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Albert Einstein College of Medicine
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Robert Kaplan
Professor of Epidemiology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Robert C. Kaplan, PhD
Role: PRINCIPAL_INVESTIGATOR
Albert Einstein College of Medicine
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.